Screening Challenges
Despite a 26% improvement in lung cancer survival rates over the past five years, only 16% of eligible individuals undergo screening, highlighting a significant gap compared to colorectal and breast cancer screenings.
The primary barrier to increasing screening rates is now awareness, following changes in insurance coverage that previously limited access to lung cancer screenings.
Treatment Innovations and Barriers
Biomarker testing, which has revolutionized lung cancer treatment by targeting specific genetic mutations, remains underutilized due to cost, with only 15 states requiring insurance coverage for comprehensive testing.
While biomarker testing offers more precise treatment options, the lack of widespread insurance coverage and high costs limit access for many patients, underscoring the need for policy improvements.